Globaldata Tracks HTA Decisions and New Drug Market Entry in 5EU

Globaldata’s analysis tracks health technology assessment (HTA) outcomes in the 5EU and the market entry of new, priced, innovative drugs. The analysis specifically examines the decisions made by health technology assessment bodies within the five largest European Union economies (5EU). Furthermore, the tracking process includes the examination of when newly priced and innovative pharmaceuticals become available to patients in these markets. These two indicators provide a snapshot of pharmaceutical access and adoption trends across major European healthcare systems.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Author

Mark Chiang